Defining the HIV neutralizing activity of antiproteases within the female genital tract and evaluating the HIV inhibitory mechanism of Serpin B1

Show simple item record

dc.contributor.supervisor Ball, T. Blake (Medical Microbiology and Infectious Diseases) en_US
dc.contributor.author Aboud, Lindsay
dc.date.accessioned 2017-01-06T21:18:59Z
dc.date.available 2017-01-06T21:18:59Z
dc.date.issued 2014-01 en_US
dc.identifier.citation Lindsay Aboud, Terry Blake Ball, Annelie Tjernlund, Adam Burgener. The role of Serpin and Cystatin antiproteases in mucosal innate immunity and their defense against HIV. AJRI, 2014; 71(1):12-23. en_US
dc.identifier.uri http://hdl.handle.net/1993/31996
dc.description.abstract The HIV/AIDS pandemic continues to be one of the most devastating global health pandemics in history. With women accounting for approximately 60% of all new HIV infections, preventative strategies that provide women with the ability to protect themselves is imperative. To this end, identifying natural factors expressed in the female genital tract (FGT) capable of inhibiting HIV may prove to be novel candidates for female-controlled microbicide preventative strategies. The work in this thesis examined the differences in CVL (cervicovaginal lavage) composition between HESN (HIV-exposed seronegative) women and HIV-susceptible women. Distinct differences in the female genital tract proteomes, and HIV inhibitory activity exhibited by CVL, were observed among women highly exposed to HIV compared to women at lower exposure. Furthermore, while HESN women as a group did not demonstrate stronger inhibitory effects compared to susceptible women from the Pumwani cohort, it was apparent that CVL from individual women was capable of inhibiting HIV consistently over longitudinal analysis. From the antiproteases that were identified as over-expressed within the CVL of HESN women, Serpin B1 exhibited the strongest and most consistent HIV inhibitory activity. The mechanism for this activity does not appear to be directly against HIV but rather through effects exerted on HIV target cells. Specifically, Serpin B1 alters the proliferative capacity and induces early apoptotic markers on these cells. Proteomic pathway analysis of the proteins over-expressed following treatment, suggests that Serpin B1 may up-regulate the expression of proteins associated with inhibition of the mTOR pathway. This inhibition may be caused by induction of increased production of ROS (reactive oxygen species) by macrophages or through Granzyme A activity, and subsequent dysfunction of the mitochondria, potentially inducing an autophagic state. However, this would need to be confirmed with further molecular studies. These results defined a potential mechanism of HIV inhibition for Serpin B1. Hence, the overabundance of Serpin B1 in the CVL of HESN women may, in fact, be contributing to their protective phenotype against HIV infection. These findings suggest that Serpin B1 could be considered as a candidate in future microbicides. However, these findings must be validated in in vivo models. en_US
dc.publisher American Journal of Reproductive Immunology en_US
dc.subject HIV/AIDS en_US
dc.subject Antiprotease en_US
dc.subject Mucosal Immunology en_US
dc.subject Microbiology en_US
dc.subject Microbicides en_US
dc.title Defining the HIV neutralizing activity of antiproteases within the female genital tract and evaluating the HIV inhibitory mechanism of Serpin B1 en_US
dc.degree.discipline Medical Microbiology en_US
dc.contributor.examiningcommittee Yao, Xiao-Yian (Medical Microbiology and Infectious Diseases) Douville, Renee (Immunology) Burgener, Adam (Medical Microbiology and Infectious Diseases) Rugeles, Maria (Medicine at University of Antioquia) en_US
dc.degree.level Doctor of Philosophy (Ph.D.) en_US
dc.description.note February 2017 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics